ArticleBMJ case reports2019
Metastatic porocarcinoma achieving complete radiological and clinical response with pembrolizumab.
Article in BMJ case reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it, 39 citations in OpenAlex.
- S1 guideline sweat gland carcinoma.Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2026Guideline
- Porocarcinoma: Clinical and Histological Features, Immunohistochemistry and Outcomes: A Systematic Review.International journal of molecular sciences · 2024Pooled it
- Anti-PD-1 monoclonal antibody combined with chemotherapy for porocarcinoma: a case report and literature review.Frontiers in oncology · 2026Article
- Stable Disease Achieved with Sequential Immunochemotherapy and Anti-Angiogenic TKI in Recurrent Metastatic Hidradenocarcinoma: A Case Report and Literature Review.Oncology research · 2026Review
- PD-1 monoclonal antibodies as an effective treatment for rare cutaneous malignancies: a case report.Frontiers in oncology · 2025Article
- Metastatic porocarcinoma: A case demonstrating objective response to pembrolizumab.JAAD case reports · 2024Article
- Case report: Pilomatrix carcinoma with PDL1 expression andFrontiers in immunology · 2024Article
- Pazopanib elicits remarkable response in metastatic porocarcinoma: a functional precision medicine approach.Cold Spring Harbor molecular case studies · 2023Article
- Eccrine Porocarcinoma: Clinical and Histopathological Study of 14 Patients with Special Emphasis on Sentinel Lymph Node Biopsy.Acta dermato-venereologica · 2023Article
- Eccrine Porocarcinoma: A Review of the Literature.Diagnostics (Basel, Switzerland) · 2023Review
- Case report: Case report and literature review: Treatment of sweat gland carcinoma.Frontiers in oncology · 2023Article
- Diagnosis and Management of Porocarcinoma.Cancers · 2022Review
- YAP1-NUTM1 Gene Fusion in Eccrine Porocarcinoma with Late Metastatic Recurrence: A Case Report.Acta dermato-venereologica · 2022Article
- Current Treatment Options for Cutaneous Adnexal Malignancies.Current treatment options in oncology · 2022Review
- Porocarcinoma of the left arm: A report of a rare skin cancer case and literature review.Clinical case reports · 2022Article
- Article
- Primary Eccrine Porocarcinoma of the Breast: A Case Report and Review of Literature.Case reports in oncological medicine · 2022Article
- Article
- [Management of malignant adnexal neoplasms of the skin].Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete · 2021Article
- Management of brain metastasis from eccrine porocarcinoma: illustrative case.Journal of neurosurgery. Case lessons · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A 67-year-old woman presented in 2012 with a crusty nodule on the left lower limb. Histopathological examination at this time reported a poorly differentiated squamous cell carcinoma (SCC). Two years later, she underwent lymphadenectomy and radiotherapy due to unilateral inguinal and pelvic sidewall nodal metastases. The following year she required excision of two subcutaneous lesions, reported pathologically to be SCC metastases. Further imaging following cyberknife radiotherapy to new brain metastases demonstrated widespread metastatic visceral disease. Twelve cycles of carboplatin and capecitabine failed to halt disease progression. In February 2017, she commenced pembrolizumab, achieving an excellent response and currently has no clinical or radiological evidence of disease. Given the unusual behaviour of her cancer, a histopathological review was requested. The diagnosis was revised to that of porocarcinoma (PC). This represents the first documented case of PC treated with immunotherapy. As of March 2019, the patient remains free of disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.